



SymBio Pharmaceuticals Limited

San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiosis.co.jp/>

April 2, 2009

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director
President and Chief Executive Officer

SymBio Pharmaceuticals Limited Concludes Sublicense Agreement Granting Cephalon, Inc. Development and Commercialization Rights for Bendamustine Hydrochloride in China

TOKYO, Japan, April 2, 2009 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio,") announced today that it has concluded a sublicense agreement with Cephalon, Inc. (Headquarters: Frazer, Pennsylvania) for the development and commercialization of SyB L-0501 (bendamustine hydrochloride) in China (including Hong Kong). SymBio has been conducting clinical studies using SyB L-0501 for the treatment of indolent and aggressive non-Hodgkin's lymphoma in Japan. Under this agreement, SymBio shall grant exclusive development and commercialization rights for China (HK) to Cephalon.

Cephalon was granted marketing approvals for bendamustine hydrochloride (TREANDA[®]) by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic lymphocytic leukemia, and indolent B-cell non-Hodgkin's lymphoma in March and October of 2008, respectively. For more information about Cephalon (NASDAQ: CEPH), please visit <http://www.cephalon.com>

The licensor of SyB- L-0501 (bendamustine hydrochloride) is Astellas Deutschland GmbH, a German affiliate of Astellas Pharma Inc. Cephalon holds development and commercialization rights to bendamustine hydrochloride in the United States and Canada. SymBio Pharmaceuticals Ltd. received exclusive rights from Astellas Deutschland GmbH for the development and commercialization of SyB L-0501 (bendamustine HCl) in Japan in December 2005 and in additional Asia Pacific countries (China (HK), Taiwan, Korea and Singapore) in March 2007. SymBio and Eisai Co., Ltd. executed a license agreement for the co-development and commercialization of SyB L-0501 in Japan in August 2008.

[Company Profile]

SymBio Pharmaceuticals Ltd. was established in March 2005 by Fuminori Yoshida, who previously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan (currently Takeda Bio Development Center Limited). The company's underlying corporate philosophy is "delivering hope to patients in need," and the company aims to address unmet medical needs of patients in Japan and other Asia Pacific regions by cultivating a mutually beneficial or symbiotic relationship among physicians, scientists, investors, government, and patients in the healthcare industry.

[Contact]

SymBio Pharmaceuticals Limited.

Tatsuya Yoneyama,

Senior Director, Business Development

Tel: + 81-3-5472-1123

E-mail: Please send your inquiry through “INQUIRY” in our homepage.

URL: <http://www.symbiosis.co.jp>